Abstract: The present disclosure provides compositions and methods for improved pre-targeted radioimmunotherapeutics (PRIT) to treat various hematological disorders, such as B cell hyperproliferative disorders and solid tumors. The disclosed compositions include bispecific antibody compositions having a first domain that specifically bind to an antigen such as CD38, BCMA, Muc1, GPRC5D, or Slam7 and a second domain that specifically binds to a radioactive ligand. Methods include administering the disclosed bispecific antibody reagent and separately administering the radioactive ligand. In some embodiments, a clearing agent is also administered. In some embodiments, the therapeutic methods comprise administering a combination of two or more bispecific antibody reagents. In some embodiments, an enhancing agent, such as ATRA, gamma secretase inhibitor, or dextramethasone, is also administered to enhance expression of the target antigen on the target cells.
Type:
Application
Filed:
November 8, 2018
Publication date:
June 10, 2021
Applicants:
Fred Hutchinson Cancer Research Center, Massachusetts Institute of Technology
Inventors:
Damian J. Green, Yukang Lin, Oliver W. Press (Deceased), Alice Tzeng, Karl Dane Wittrup
Abstract: The present disclosure provides TCRs with high or enhanced affinity against various tumor associated antigens (including human Wilms tumor protein 1 (WT 1) epitopes and mesothelin epitopes), T cells expressing such high affinity antigen specific TCRs, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells overexpress one or more of these antigens, such as in cancer.
Type:
Grant
Filed:
December 23, 2016
Date of Patent:
June 8, 2021
Assignees:
Fred Hutchinson Cancer Research Center, Adaptive Biotechnologies Corporation
Inventors:
Thomas M. Schmitt, Philip D. Greenberg, Aude G. Chapuis, Harlan S. Robins, Anna M. Sherwood
Abstract: Methods to create barcoded influenza viruses without disrupting the function of the viral proteins and the proper packaging of the viral genome segments are described. The barcoded influenza viruses can be used within deep mutational scanning libraries to map influenza resistance mutations to therapeutic treatments. The libraries can also be used to predict influenza strains that may become resistant to therapeutic treatments and/or more easily evolve to infect new species. The libraries include features that allow efficient collection and assessment of informative data, obviating bottlenecks of previous approaches.
Type:
Application
Filed:
November 13, 2020
Publication date:
May 20, 2021
Applicant:
FRED HUTCHINSON CANCER RESEARCH CENTER
Inventors:
Jesse Bloom, Allison Greaney, Andrea Loes, Adam S. Dingens
Abstract: Treatment protocols based on expression of therapeutic proteins by genetically-modified selected cell types in vivo are described. The treatment protocols can additionally utilize cell attractants to attract selected cell types to a treatment site and/or macrophage activation protocols at the treatment site.
Abstract: Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp120) and can used as an HIV vaccine.
Type:
Grant
Filed:
June 3, 2019
Date of Patent:
April 27, 2021
Assignee:
Fred Hutchinson Cancer Research Center
Inventors:
Roland K. Strong, Colin Correnti, Leonidas Stamatatos, Andrew McGuire
Abstract: Methods to promote thymic regeneration are described. The methods can inhibit nucleotide-binding oligomerization domain-containing protein 2 (NOD2), Rho GTPases, and/or microRNA 29c (miR29c). These inhibition methods can promote regenerative molecules, such as interleukin (IL)-22, IL-23, and/or bone morphogenetic protein 4 (BMP4). Promoting thymic regeneration can be beneficial in patients due to age, infection, or cancer therapies.
Abstract: The present disclosure relates to anti-ROR1 binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.
Type:
Grant
Filed:
February 2, 2017
Date of Patent:
April 6, 2021
Assignee:
FRED HUTCHINSON CANCER RESEARCH CENTER
Inventors:
Ashwini Balakrishnan, Benjamin G. Hoffstrom, Julie Randolph-Habecker, Stanley R. Riddell
Abstract: The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount. The method comprises administering as the CTL preparation a preparation consisting essentially of an in vitro expanded primate CTL population, the CTL population enriched prior to expansion for central memory T lymphocytes, and depleted prior to expansion of effector memory T lymphocytes. In some embodiments, the method may further comprise concurrently administering Interleukin-15 to the subject in an amount effective to increase the proliferation of the central memory T cells in the subject. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
Type:
Grant
Filed:
July 17, 2019
Date of Patent:
April 6, 2021
Assignees:
City of Hope, Fred Hutchinson Cancer Research Center
Inventors:
Stanley R. Riddell, Susanna Carolina Berger, Michael C. Jensen
Abstract: Small cell lung cancer specific chimeric antigen receptor comprising: an antigen-binding domain capable of specifically binding an antigen selected from Tables 1A, 1B, 2A, 2B and 4 and/or that specifically binds to or interacts GAD65, PTPRU, TFRC and GABA-b. A method for treating a subject suffering from SCLC comprising, introducing into the subject a therapeutically effective amount of a T lymphocyte comprising a chimeric antigen receptor. An antigen binding molecule, comprising: an antigen-binding domain capable of specifically binding an antigen selected from Tables 1A, 1B, 2A, 2B and 4 and/or that specifically binds to or interacts GAD65, PTPRU, TFRC and GABA-b. A method of detecting an SCLC tumor in a subject.
Type:
Application
Filed:
September 18, 2020
Publication date:
March 25, 2021
Applicant:
FRED HUTCHINSON CANCER RESEARCH CENTER
Inventors:
Paul Lampe, Ashley McGarry Houghton, Kristin Lastwika
Abstract: Methods to create chemically-induced dimerizing (CID) protein systems and uses thereof are described. The methods utilize antibody binding domain dimerizing proteins. The created systems can be used to regulate cellular events such as gene expression, receptor signaling and cell death to effectuate a variety of clinically relevant treatment outcomes.
Abstract: A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.
Abstract: The present disclosure relates to anti-ROR1 binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.
Type:
Grant
Filed:
February 2, 2017
Date of Patent:
February 23, 2021
Assignee:
FRED HUTCHINSON CANCER RESEARCH CENTER
Inventors:
Ashwini Balakrishnan, Benjamin G. Hoffstrom, Julie Randolph-Habecker, Stanley R. Riddell
Abstract: Systems and methods to modulate the activation state of immune cells in vivo are described. The systems and methods can be used to transform immunosuppressive macrophages that support cancer growth and metastasis into highly activated tumoricidal macrophages.
Abstract: The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize heme proteins, iron and/or vitamin B12 and, optionally, agents that impact heme protein metabolism.
Abstract: The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.
Abstract: Water delivery apparatuses and associated methods that minimize the amount of time and preparation and/or maintenance work required for a user to supply water to one or more animals are disclosed. In an aspect, water delivery apparatuses and associated methods of use are disclosed that are configured to maintain a substantially consistent water quantity within at least one water reservoir that provides drinkable water to one or more animals. The substantially consistent water quantity may be maintained by configuring at least one float mechanism that comprises at least one sealing element to at least partially block at least one orifice associated with at least one water supply inlet connected to a continuous water supply once the water within the reservoir reaches a certain level, thereby slowing and/or stopping the incoming water flow.
Abstract: In one aspect, the present invention provides an intron-modified capsid expression cassette useful for generating adeno-associated virus (AAV) vector particles. In another aspect, the present invention provides a method of reducing the immune response in a mammalian subject undergoing treatment with an AAV vector.
Type:
Application
Filed:
July 30, 2020
Publication date:
January 14, 2021
Applicant:
Fred Hutchinson Cancer Research Center
Inventors:
Arthur Dusty Miller, Christine L. Halbert, Michael J. Metzger
Abstract: The present disclosure provides methods for generating enhanced affinity T cell receptors by agonist selection of hematopoietic progenitor cells expressing an antigen specific TCR? cultured with stromal cells expressing Delta-like-1 or Delta-like-4, compositions prepared from such methods, and uses of thereof.
Abstract: The present disclosure provides compositions and uses thereof for treating a disease or disorder associated with CD20 expression. Treatments of this disclosure include use of a host cell expressing a fusion protein, such as an anti-CD20 CAR, optionally in combination with a CD20-specific binding molecule, a chemotherapeutic, an inhibitor of an immunosuppression component, or combinations thereof.
Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
Type:
Grant
Filed:
October 18, 2019
Date of Patent:
December 22, 2020
Assignees:
Fred Hutchinson Cancer Research Center, Seattle Children's Hospital
Inventors:
Michael C. Jensen, Stanley R. Riddell, Michael Hudecek